C Lorenzo1, A J Hanley, M J Rewers, S M Haffner. 1. Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. lorenzo@uthscsa.edu
Abstract
AIMS/HYPOTHESIS: Markers of liver injury, such as alanine aminotransferase (ALT), have been associated with atherogenic lipoprotein changes. We examined the extent to which this association was explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation. METHODS: In this analysis we included 824 non-diabetic participants (age 40-69 years) in the Insulin Resistance Atherosclerosis Study. No participants reported excessive alcohol intake or treatment with lipid-lowering medications. Lipoproteins and apolipoproteins were measured by conventional methods and lipoprotein heterogeneity by nuclear magnetic resonance (NMR) spectroscopy. RESULTS: ALT had a positive relationship with triacylglycerols, LDL-to-HDL-cholesterol ratio and apolipoprotein B (ApoB) after adjusting for demographic variables (p < 0.001 for all three relationships). ALT was also associated with the following NMR lipoproteins: positively with large VLDL (p < 0.001), intermediate-density lipoprotein (IDL) (p < 0.001) and small LDL subclass particles (p < 0.001), and VLDL particle size (p < 0.001); and negatively with large LDL subclass particles (p < 0.05) and LDL (p < 0.001) and HDL particle sizes (p < 0.01). ALT remained associated with IDL and small LDL subclass particles and ApoB after adjusting for glucose tolerance, adiposity, directly measured insulin sensitivity and C-reactive protein. CONCLUSIONS/ INTERPRETATION: ALT is associated with a wide range of atherogenic lipoprotein changes, which are partially explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation. Because of the significant variability in the relationship between ALT and liver fat, further studies are needed to assess the extent of the lipoprotein changes using a direct measure of liver fat.
AIMS/HYPOTHESIS: Markers of liver injury, such as alanine aminotransferase (ALT), have been associated with atherogenic lipoprotein changes. We examined the extent to which this association was explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation. METHODS: In this analysis we included 824 non-diabeticparticipants (age 40-69 years) in the Insulin Resistance Atherosclerosis Study. No participants reported excessive alcohol intake or treatment with lipid-lowering medications. Lipoproteins and apolipoproteins were measured by conventional methods and lipoprotein heterogeneity by nuclear magnetic resonance (NMR) spectroscopy. RESULTS: ALT had a positive relationship with triacylglycerols, LDL-to-HDL-cholesterol ratio and apolipoprotein B (ApoB) after adjusting for demographic variables (p < 0.001 for all three relationships). ALT was also associated with the following NMR lipoproteins: positively with large VLDL (p < 0.001), intermediate-density lipoprotein (IDL) (p < 0.001) and small LDL subclass particles (p < 0.001), and VLDL particle size (p < 0.001); and negatively with large LDL subclass particles (p < 0.05) and LDL (p < 0.001) and HDL particle sizes (p < 0.01). ALT remained associated with IDL and small LDL subclass particles and ApoB after adjusting for glucose tolerance, adiposity, directly measured insulin sensitivity and C-reactive protein. CONCLUSIONS/ INTERPRETATION: ALT is associated with a wide range of atherogenic lipoprotein changes, which are partially explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation. Because of the significant variability in the relationship between ALT and liver fat, further studies are needed to assess the extent of the lipoprotein changes using a direct measure of liver fat.
Authors: M A Bethel; P Deedwania; N S Levitt; O Schmitz; A Huntsman-Labed; R M Califf; S M Haffner; P Diem Journal: Diabet Med Date: 2009-12 Impact factor: 4.359
Authors: Ryan L McKimmie; Kurt R Daniel; J Jeffrey Carr; Donald W Bowden; Barry I Freedman; Thomas C Register; Fang-Chi Hsu; Kurt K Lohman; Richard B Weinberg; Lynne E Wagenknecht Journal: Am J Gastroenterol Date: 2008-10-03 Impact factor: 10.864
Authors: Samia Mora; James D Otvos; Robert S Rosenson; Aruna Pradhan; Julie E Buring; Paul M Ridker Journal: Diabetes Date: 2010-02-25 Impact factor: 9.461
Authors: Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein Journal: Proc Natl Acad Sci U S A Date: 2009-08-24 Impact factor: 11.205
Authors: Mohammad S Siddiqui; Michael Fuchs; Michael O Idowu; Velimir A Luketic; Sherry Boyett; Carol Sargeant; Richard T Stravitz; Puneet Puri; Scott Matherly; Richard K Sterling; Melissa Contos; Arun J Sanyal Journal: Clin Gastroenterol Hepatol Date: 2014-10-13 Impact factor: 11.382
Authors: M Shadab Siddiqui; Richard K Sterling; Velimir A Luketic; Puneet Puri; R Todd Stravitz; Iliana Bouneva; Sherry Boyett; Michael Fuchs; Carol Sargeant; G Russell Warnick; Shahrzad Grami; Arun J Sanyal Journal: Gastroenterology Date: 2013-08-21 Impact factor: 22.682
Authors: Noor Suleiman; Meis Alkasem; Shaimaa Hassoun; Ibrahem Abdalhakam; Ilham Bettahi; Fayaz Mir; Manjunath Ramanjaneya; Jayakumar Jerobin; Ahmad Iskandarani; Tareq A Samra; Prem Chandra; Monica Skarulis; Abdul Badi Abou-Samra Journal: BMJ Open Diabetes Res Care Date: 2021-11
Authors: Anna E Garcia; Nader Kasim; Robyn A Tamboli; Raul S Gonzalez; Joseph Antoun; Emily A Eckert; Pamela A Marks-Shulman; Julia Dunn; Julia Wattacheril; Taylor Wallen; Naji N Abumrad; Charles Robb Flynn Journal: PLoS One Date: 2015-11-23 Impact factor: 3.240